Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant

Mary D. Thoma, Tanya J. Huneke, Lori J. DeCook, Nicci D. Johnson, Rob A. Wiegand, Mark R Litzow, William Hogan, Luis F. Porrata, Shernan G. Holtan

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Many previous studies of immune reconstitution (IR) postallogeneic hematopoietic stem cell transplantation (HSCT) have focused on lymphocyte recovery. Recognizing that IR involves complex interactions between innate and adaptive immune networks, we hypothesized that patterns of both monocyte and lymphocyte recovery could provide additional prognostic information. To test our hypothesis, we analyzed data from 135 consecutive patients undergoing myeloablative allogeneic HSCT for acute myeloid (AML) and lymphoblastic leukemia (ALL) from 2001 to 2010. The absolute lymphocyte and monocyte counts (ALC and AMC, respectively) were determined longitudinally at days +15, +30, +60, and +100, and correlated with clinical outcomes. At the day +30 time point, both ALC and AMC >0.3 × 109 cells/L were strongly associated with improved survival (overall survival [OS] 29.6 months versus 5.4 months, P = 006 and 25.3 months versus 5.1 months, P = 01 respectively), a pattern that generally continued through the day +100 evaluation. Multivariate analysis revealed the following independent prognostic factors: early disease status at transplantation, the development of chronic GVHD, the day +30 AMC, day +100 AMC, and day +100 ALC. To further explore whether any inherent patterns in the timing of lymphocyte and monocyte recovery had prognostic value post-HSCT, we performed unsupervised hierarchical clustering on the longitudinal hematopoietic parameters studied in this cohort. Four clusters of patients were identified: clusters A-D. Patient clusters B and D both demonstrated improved ALC and AMC recovery at the day +60 and day +100 time points and had significantly improved OS compared with clusters A and C (57.8 months versus 19.7 and 4.4 months, respectively, P < 001). Our data suggest that patients with poor lymphocyte and monocyte recovery beyond the day +60 time points may be at risk for poorer outcomes, and that further investigation into lymphoid/myeloid interactions in developing individualized immunotherapy is warranted.

Original languageEnglish (US)
Pages (from-to)600-607
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Hematopoietic Stem Cells
Monocytes
Hematopoietic Stem Cell Transplantation
Leukemia
Lymphocytes
Transplants
Survival
Lymphocyte Count
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Immunotherapy
Cluster Analysis
Multivariate Analysis
Transplantation

Keywords

  • Acute leukemia
  • Allogeneic transplant
  • Immune reconstitution
  • Lymphocyte
  • Monocyte
  • Myeloablative

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. / Thoma, Mary D.; Huneke, Tanya J.; DeCook, Lori J.; Johnson, Nicci D.; Wiegand, Rob A.; Litzow, Mark R; Hogan, William; Porrata, Luis F.; Holtan, Shernan G.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 4, 04.2012, p. 600-607.

Research output: Contribution to journalArticle

Thoma, Mary D. ; Huneke, Tanya J. ; DeCook, Lori J. ; Johnson, Nicci D. ; Wiegand, Rob A. ; Litzow, Mark R ; Hogan, William ; Porrata, Luis F. ; Holtan, Shernan G. / Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 4. pp. 600-607.
@article{c5a370a3ccb94098b953106528d0545b,
title = "Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant",
abstract = "Many previous studies of immune reconstitution (IR) postallogeneic hematopoietic stem cell transplantation (HSCT) have focused on lymphocyte recovery. Recognizing that IR involves complex interactions between innate and adaptive immune networks, we hypothesized that patterns of both monocyte and lymphocyte recovery could provide additional prognostic information. To test our hypothesis, we analyzed data from 135 consecutive patients undergoing myeloablative allogeneic HSCT for acute myeloid (AML) and lymphoblastic leukemia (ALL) from 2001 to 2010. The absolute lymphocyte and monocyte counts (ALC and AMC, respectively) were determined longitudinally at days +15, +30, +60, and +100, and correlated with clinical outcomes. At the day +30 time point, both ALC and AMC >0.3 × 109 cells/L were strongly associated with improved survival (overall survival [OS] 29.6 months versus 5.4 months, P = 006 and 25.3 months versus 5.1 months, P = 01 respectively), a pattern that generally continued through the day +100 evaluation. Multivariate analysis revealed the following independent prognostic factors: early disease status at transplantation, the development of chronic GVHD, the day +30 AMC, day +100 AMC, and day +100 ALC. To further explore whether any inherent patterns in the timing of lymphocyte and monocyte recovery had prognostic value post-HSCT, we performed unsupervised hierarchical clustering on the longitudinal hematopoietic parameters studied in this cohort. Four clusters of patients were identified: clusters A-D. Patient clusters B and D both demonstrated improved ALC and AMC recovery at the day +60 and day +100 time points and had significantly improved OS compared with clusters A and C (57.8 months versus 19.7 and 4.4 months, respectively, P < 001). Our data suggest that patients with poor lymphocyte and monocyte recovery beyond the day +60 time points may be at risk for poorer outcomes, and that further investigation into lymphoid/myeloid interactions in developing individualized immunotherapy is warranted.",
keywords = "Acute leukemia, Allogeneic transplant, Immune reconstitution, Lymphocyte, Monocyte, Myeloablative",
author = "Thoma, {Mary D.} and Huneke, {Tanya J.} and DeCook, {Lori J.} and Johnson, {Nicci D.} and Wiegand, {Rob A.} and Litzow, {Mark R} and William Hogan and Porrata, {Luis F.} and Holtan, {Shernan G.}",
year = "2012",
month = "4",
doi = "10.1016/j.bbmt.2011.08.007",
language = "English (US)",
volume = "18",
pages = "600--607",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant

AU - Thoma, Mary D.

AU - Huneke, Tanya J.

AU - DeCook, Lori J.

AU - Johnson, Nicci D.

AU - Wiegand, Rob A.

AU - Litzow, Mark R

AU - Hogan, William

AU - Porrata, Luis F.

AU - Holtan, Shernan G.

PY - 2012/4

Y1 - 2012/4

N2 - Many previous studies of immune reconstitution (IR) postallogeneic hematopoietic stem cell transplantation (HSCT) have focused on lymphocyte recovery. Recognizing that IR involves complex interactions between innate and adaptive immune networks, we hypothesized that patterns of both monocyte and lymphocyte recovery could provide additional prognostic information. To test our hypothesis, we analyzed data from 135 consecutive patients undergoing myeloablative allogeneic HSCT for acute myeloid (AML) and lymphoblastic leukemia (ALL) from 2001 to 2010. The absolute lymphocyte and monocyte counts (ALC and AMC, respectively) were determined longitudinally at days +15, +30, +60, and +100, and correlated with clinical outcomes. At the day +30 time point, both ALC and AMC >0.3 × 109 cells/L were strongly associated with improved survival (overall survival [OS] 29.6 months versus 5.4 months, P = 006 and 25.3 months versus 5.1 months, P = 01 respectively), a pattern that generally continued through the day +100 evaluation. Multivariate analysis revealed the following independent prognostic factors: early disease status at transplantation, the development of chronic GVHD, the day +30 AMC, day +100 AMC, and day +100 ALC. To further explore whether any inherent patterns in the timing of lymphocyte and monocyte recovery had prognostic value post-HSCT, we performed unsupervised hierarchical clustering on the longitudinal hematopoietic parameters studied in this cohort. Four clusters of patients were identified: clusters A-D. Patient clusters B and D both demonstrated improved ALC and AMC recovery at the day +60 and day +100 time points and had significantly improved OS compared with clusters A and C (57.8 months versus 19.7 and 4.4 months, respectively, P < 001). Our data suggest that patients with poor lymphocyte and monocyte recovery beyond the day +60 time points may be at risk for poorer outcomes, and that further investigation into lymphoid/myeloid interactions in developing individualized immunotherapy is warranted.

AB - Many previous studies of immune reconstitution (IR) postallogeneic hematopoietic stem cell transplantation (HSCT) have focused on lymphocyte recovery. Recognizing that IR involves complex interactions between innate and adaptive immune networks, we hypothesized that patterns of both monocyte and lymphocyte recovery could provide additional prognostic information. To test our hypothesis, we analyzed data from 135 consecutive patients undergoing myeloablative allogeneic HSCT for acute myeloid (AML) and lymphoblastic leukemia (ALL) from 2001 to 2010. The absolute lymphocyte and monocyte counts (ALC and AMC, respectively) were determined longitudinally at days +15, +30, +60, and +100, and correlated with clinical outcomes. At the day +30 time point, both ALC and AMC >0.3 × 109 cells/L were strongly associated with improved survival (overall survival [OS] 29.6 months versus 5.4 months, P = 006 and 25.3 months versus 5.1 months, P = 01 respectively), a pattern that generally continued through the day +100 evaluation. Multivariate analysis revealed the following independent prognostic factors: early disease status at transplantation, the development of chronic GVHD, the day +30 AMC, day +100 AMC, and day +100 ALC. To further explore whether any inherent patterns in the timing of lymphocyte and monocyte recovery had prognostic value post-HSCT, we performed unsupervised hierarchical clustering on the longitudinal hematopoietic parameters studied in this cohort. Four clusters of patients were identified: clusters A-D. Patient clusters B and D both demonstrated improved ALC and AMC recovery at the day +60 and day +100 time points and had significantly improved OS compared with clusters A and C (57.8 months versus 19.7 and 4.4 months, respectively, P < 001). Our data suggest that patients with poor lymphocyte and monocyte recovery beyond the day +60 time points may be at risk for poorer outcomes, and that further investigation into lymphoid/myeloid interactions in developing individualized immunotherapy is warranted.

KW - Acute leukemia

KW - Allogeneic transplant

KW - Immune reconstitution

KW - Lymphocyte

KW - Monocyte

KW - Myeloablative

UR - http://www.scopus.com/inward/record.url?scp=84858059022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858059022&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.08.007

DO - 10.1016/j.bbmt.2011.08.007

M3 - Article

C2 - 21843495

AN - SCOPUS:84858059022

VL - 18

SP - 600

EP - 607

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 4

ER -